Characterization and prognostic implication of delayed complete response in AL amyloidosis. (4th December 2020)
- Record Type:
- Journal Article
- Title:
- Characterization and prognostic implication of delayed complete response in AL amyloidosis. (4th December 2020)
- Main Title:
- Characterization and prognostic implication of delayed complete response in AL amyloidosis
- Authors:
- Muchtar, Eli
Gertz, Morie A.
Kumar, Shaji K.
Lacy, Martha Q.
Leung, Nelson
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Go, Ronald S.
Kapoor, Prashant
Gonsalves, Wilson
Kourelis, Taxiarchis V.
Warsame, Rahma
Lisa Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Russell, Stephen
Lust, John A.
Siddiqui, Mustaqueem
Vincent Rajkumar, S.
Kyle, Robert A.
Dispenzieri, Angela - Abstract:
- Abstract: Introduction: Little is known on continued response following completion of therapy in light chain (AL) amyloidosis. Methods: We studied 373 AL amyloidosis patients who achieved complete response (CR) or very good partial response (VGPR) to first‐line therapy. Results: By end of therapy (EOT), 46% of patients achieved a CR and 54% a VGPR. With no further therapy, 17.5% of patients were upstaged from VGPR to CR (delayed CR), with a median of 9 months. Compared with CR and VGPR at EOT, patients with a delayed CR were characterized by higher proportion of t (11;14) and lower rate of trisomies. Autologous stem cell transplant was more frequent in the delayed CR group. Patients with a delayed CR were characterized by minimal residual disease negativity and organ response rates similar to patients with CR at EOT and higher than patients achieving VGPR at EOT. Patients with a delayed CR had a longer PFS/OS compared to patients with CR or VGPR by EOT (median PFS 149 vs 92 vs 52 months, P < .001; 10‐year OS 87% vs 71% vs 56%, P < .001). Conclusions: This study characterizes delayed CR in AL amyloidosis, highlights its prognostic impact which is at least similar to those who achieved CR at EOT, and underlines another aspect of response monitoring.
- Is Part Of:
- European journal of haematology. Volume 106:Number 3(2021)
- Journal:
- European journal of haematology
- Issue:
- Volume 106:Number 3(2021)
- Issue Display:
- Volume 106, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 106
- Issue:
- 3
- Issue Sort Value:
- 2021-0106-0003-0000
- Page Start:
- 354
- Page End:
- 361
- Publication Date:
- 2020-12-04
- Subjects:
- autologous stem cell transplant -- immunoparesis -- off‐therapy -- survival
Hematology -- Periodicals
Blood -- Diseases -- Periodicals
Blood -- Periodicals
616.15005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-0609 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=ejh ↗
http://onlinelibrary.wiley.com/ ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1111/ejh.13554 ↗
- Languages:
- English
- ISSNs:
- 0902-4441
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.729700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22599.xml